Hamadani, Mehdi; Kanate, Abraham S; DiGilio, Alyssa; Ahn, Kwang Woo; Smith, Sonali M; Lee, Jong Wook; Ayala, Ernesto; Chao, Nelson; Hari, Parameswaran; Bolanos-Meade, Javier; Gress, Ronald; Smedegaard Anderson, Niels; Chen, Yi-Bin; Farooq, Umar; Schiller, Gary; Yared, Jean; Sureda, Anna; Fenske, Timothy S; Olteanu, Horatiu
Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation
2017May ; 23 ( 5 ) :853-856.
PMID : 28161608
ÀúÀÚ »ó¼¼Á¤º¸
Hamadani, Mehdi -
Kanate, Abraham S -
DiGilio, Alyssa -
Ahn, Kwang Woo -
Smith, Sonali M -
Lee, Jong Wook -
Ayala, Ernesto -
Chao, Nelson -
Hari, Parameswaran -
Bolanos-Meade, Javier -
Gress, Ronald -
Smedegaard Anderson, Niels -
Chen, Yi-Bin -
Farooq, Umar -
Schiller, Gary -
Yared, Jean -
Sureda, Anna -
Fenske, Timothy S -
Olteanu, Horatiu -
ABSTRACT
Aggressive NK cell leukemia (ANKL) is an exceedingly rare form of leukemia and carries a poor prognosis, with a median survival of only 2 months. Using the Center for International Blood and Marrow Transplant Research database, we evaluated outcomes of allogeneic hematopoietic cell transplantation (alloHCT) in patients with ANKL. Twenty-one patients with a centrally confirmed diagnosis of ANKL were included. Median patient age was 42 years and 15 patients (71%) were Caucasian. Fourteen patients (67%) were in complete remission (CR) at the time of alloHCT, and 5 patients had active disease. Median follow-up of survivors was 25 months (range, 12 to 116). The 2-year estimates of nonrelapse mortality, relapse/progression, progression-free (PFS), and overall survival (OS) were 21%, 59%, 20%, and 24%, respectively. The 2-year PFS of patients in CR at the time of alloHCT was significantly better than that of patients with active disease at transplantation (30% versus 0%; P?=?.001). The 2-year OS in similar order was 38% versus 0% (P?
Aggressive natural killer cell leukemia; Allogeneic transplantation; Myeloablative; Reduced-intensity conditioning
¸µÅ©